Artal Group’s LENZ Therapeutics LENZ Stock Holding History

Artal Group’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-100,000	Closed	-$2.32M	–	144
2022 Q4	$2.32M	Hold	100,000	–	–	0.13%	84
2022 Q3	$2.22M	Hold	100,000	–	–	0.12%	91
2022 Q2	$1.93M	Hold	100,000	–	–	0.11%	98
2022 Q1	$3.57M	Hold	100,000	–	–	0.15%	94
2021 Q4	$8.7M	Hold	100,000	–	–	0.26%	73
2021 Q3	$11.5M	Hold	100,000	–	–	0.28%	74
2021 Q2	$21.5M	Buy	+100,000	New	+$17.4M	0.49%	52

Other funds holding LENZ

EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return

K2 Principal Fund Toronto, Ontario, Canada $947M AUM 29.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Verition Fund Management

Verition Fund Management Greenwich, Connecticut $10.3B AUM 30.69% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return